UCB AND JAZZ PHARMACEUTICALS ANNOUNCE EXPANSION OF XYREM LICENSE AGREEMENT TO INCLUDE FIBROMYALGIA SYNDROME

UCB and Jazz Pharmaceuticals, Inc. announced the signing of an expanded product license agreement for Xyrem (sodium oxybate). Under the agreement, UCB obtains the right to commercialize Xyrem for the treatment of fibromyalgia syndrome, if and when the product is approved for this indication. On September 7th 2006, Jazz Pharmaceuticals announced the initiation of its Phase III clinical development program evaluating the use of Xyrem for the treatment of fibromyalgia syndrome. Market Wire (http://www.marketwire.com/mw/release_html_b1?release_id=168900)